Eli Lilly’s ongoing technology evaluation agreement with Peptron, signed in October 2024 and extended through October 7, 2026, remains strictly limited to non-binding joint research on SmartDepot microsphere formulations for peptide candidates, granting only internal R&D rights without commercial licensing provisions. No official announcements of a technology transfer or binding commercial deal have emerged despite nearly two years of in-vivo studies and initial validation, while Lilly actively pursues alternative long-acting platforms such as Camurus’ FluidCrystal for GLP-1 therapies. With the deadline just days away and Lilly able to exit on short notice, trader consensus reflects the low likelihood of an abrupt shift to commercial terms. The immediate resolution date itself serves as the key upcoming catalyst.